tradingkey.logo
tradingkey.logo
Pesquisar

Emergent BioSolutions Inc

EBS
Adicionar à lista de desejos
8.280USD
+0.010+0.12%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
428.90MValor de mercado
PerdaP/L TTM

Mais detalhes de Emergent BioSolutions Inc Empresa

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Informações de Emergent BioSolutions Inc

Código da empresaEBS
Nome da EmpresaEmergent BioSolutions Inc
Data de listagemNov 15, 2006
CEOPapa (Joseph C)
Número de funcionários900
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 15
Endereço300 Professional Dr
CidadeGAITHERSBURG
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal20879
Telefone12406313200
Sitehttps://emergentbiosolutions.com/
Código da empresaEBS
Data de listagemNov 15, 2006
CEOPapa (Joseph C)

Executivos da empresa Emergent BioSolutions Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
114.67K
+22.10%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
89.36K
+28.36%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
79.44K
+31.90%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
59.03K
+16.71%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%

Perguntas frequentes

Quem são os cinco principais acionistas de Emergent BioSolutions Inc?

Os cinco principais acionistas de Emergent BioSolutions Inc são: Mr. Joseph C. (Joe) Papa

Quantas instituições possuem ações da Emergent BioSolutions Inc (EBS)?

Em 2026Q1, 412 instituições possuíam ações da Emergent BioSolutions Inc, com valor de mercado aproximado de 42.30M, representando 81.98% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3370363.00.

Qual é a maior fonte de receita da Emergent BioSolutions Inc?

Em 2026Q1, o segmento de negócios Commercial Product sales gerou a maior receita para Emergent BioSolutions Inc, totalizando 223.30M e representando 30.06% da receita total.